GlassScriptPhysician profile
Kristal L Lang
NPI 1487132171
$3,883.33
in general payments reported to CMS, 2019-2025
27 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $484 · 2023: $625 · 2024: $953 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.26 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $838.81 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $463.29 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.46 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $247.31 | 2022-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $239.36 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $206.15 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $203.32 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $196.69 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $181.31 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $141.01 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $131.02 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $114.40 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $82.66 | 2023-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $63.92 | 2021-2022 | |
| Noven Therapeutics, LLC | $58.22 | 2024-2025 | Xelstrym, Secuado |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $52.33 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $46.94 | 2024 | |
| Idorsia Pharmaceuticals US INC | $44.73 | 2023-2024 | Quviviq |
| Lundbeck LLC | $41.41 | 2024-2025 | Rexulti |
| Eisai INC. | $32.34 | 2021 | |
| Vertical Pharmaceuticals, LLC | $28.31 | 2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $26.07 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $22.83 | 2025 | Jornay Pm |
| Indivior INC. | $20.66 | 2024 | Perseris |
| Jazz Pharmaceuticals INC. | $19.39 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.39 | 2021 | |
| Biogen, INC. | $15.00 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristal Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.